Nevertheless, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, in routine assessment BC is considered PgR(−) if <1% or 0% of tumor cell nuclei are immunoreactive [7]. Here, PGR is linked to neoplasm.